news
GSK to acquire BELLUS for £1.6 billion
A novel P2X3 antagonist is set to advance GSK's respiratory…
A novel P2X3 antagonist is set to advance GSK's respiratory pipeline as part of its planned £1.6 billion acquisition of BELLUS Health.
List view / Grid view
Luke Miels (GSK)
news
GSK to exclusively license novel oral antifungal
The only US Food and Drug Administration (FDA)-approved oral antifungal…
The only US Food and Drug Administration (FDA)-approved oral antifungal for vulvovaginal candidiasis will be exclusively licensed by GSK.
news
GSK will acquire Sierra Oncology to strengthen haematology arsenal
GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company…
GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specialises in treatments for rare forms of cancer.
